The Last Mile Problem: A Critical Assessment of Physics-Based and AI Tools for Small Molecule Binding Prediction in Virtual Screening
Abstract
Docking-based virtual screening (VS) is essential for hit finding in the initial stage of drug or probe discovery. However, it remains prone to high false-positive rates, often resulting in unsuccessful screening campaigns. MD-based alchemical free-energy methods offer a promising solution to improve VS hit rates but are highly resource-intensive. Real-world and benchmark studies incorporating alchemical absolute binding free energy (ABFE) calculations could help optimize their use in VS pipelines. Here, we present a large-scale benchmark to evaluate the comparative value of ABFE calculations in VS workflows. Two data sets were used: a curated set of 632 ligand-protein complexes from the PDBbind database to assess ABFE quantitative accuracy and a set of 315 binders and decoys from the Database of Useful Decoys (DUD-E) to evaluate predictive power in a VS context. Alongside alchemical ABFE, we benchmarked computationally affordable end-state physics-based methods and five machine-learning (ML) models. The study ranked BFE predictors consistently with their computational cost, with alchemical ABFE performing well across both benchmarks. End-state methods scored well in recognizing actives from decoys in the DUD-E data set but showed little correlation with experimental values in PDBbind. Most ML models performed well on PDBbind, likely due to training overlap, but failed on DUD-E, except for GNINA and Boltz-2, which demonstrated a degree of generalization comparable to…
How strong is the evidence?
Evidence Hub reads this as a simulation / modelling, done in computer models (in silico), not in people. Its evidence level is 5 of 5 (Very low · case / narrative / animal / in vitro / in silico). Case reports, narrative reviews, and animal, cell or computer-model studies give the weakest evidence for human health.
Read the paper
Related studies
- Quantum dots: synthesis, bioapplications, and toxicity
- A Guide to In Silico Drug Design
- Quantum Computing for Healthcare: A Review
- Automated in Silico Design of Homogeneous Catalysts
- Identification of Novel 3-Hydroxy-pyran-4-One Derivatives as Potent HIV-1 Integrase Inhibitors Using in silico Structure-Based Combinatorial Library Design Approach
- In silico structural elucidation of RNA-dependent RNA polymerase towards the identification of potential Crimean-Congo Hemorrhagic Fever Virus inhibitors
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.